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Abstract
Dietary fibres are frequently used for the treatment of obesity. The aim of this study was to
evaluate the efficacy of Irvingia gabonensis seeds in the management of obesity. This was carried out
as a double blind randomised study involving 40 subjects (mean age 42.4 years). Twenty-eight
subjects received Irvingia gabonensis (IG) (1.05 g three time a day for one month) while 12 were on
placebo (P) and the same schedule. During the one-month study period all subjects were on a
normocaloric diet evaluated every week by a dietetic record book. At the end, the mean body
weight of the IG group was decreased by 5.26 ± 2.37% (p < 0.0001) and that of the placebo group
by 1.32 ± 0.41% (p < 0.02). The difference observed between the IG and the placebo groups was
significant (p < 0.01). The obese patients under Irvingia gabonensis treatment also had a significant
decrease of total cholesterol, LDL-cholesterol, triglycerides, and an increase of HDL-cholesterol.
On the other hand, the placebo group did not manifest any changes in blood lipid components.
Irvingia gabonensis seed may find application in weight lose.
Introduction
Obesity is of major primary care concern and is targeted as
an international health objective in Healthy 2000, which
seeks to reduce the prevalence of obesity to less than 20%.
In the last 10 years, the number of overweight people has
increased from 26 to 34% [1]. Conventional dietary and
behavioral treatment have failed in long-term manage-
ment. Dietary strategies used to manage obesity include
the use of high fibre, low carbohydrates and fats diet [2,3].
Beneficial effect of dietary fibre in the management of
obesity is not well established, since their mechanism of
action is not known. The discovery of new medicinal
plants has led to the creation of potential drugs that mod-
ify feeding behavior and metabolism and may therefore
have application in weight management. The aim of the
present study is to investigate the effect of Irvingia gabon-
ensis extract on body weight.
Subjects and methods
A total of 40 obese subjects aged between 19 and 55 years
were selected from a group responding to a radio adver-
tisement. After physical examination and laboratory
screening tests, diabetics, pregnant and lactating women
were excluded. None of these subjects took any weight
reducing medication and none was following any specific
diet. The purpose, nature and potential risks of the study
were explained to all patients and a written informed con-
sent was obtained before their participation. The local
research ethics committee approved the experimental
protocol.
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Study design
The study was as a randomised, double blind placebo-
controlled crossover design, and consisted of a 4-week
treatment period. Subjects were given two different types
of capsules containing 350 mg of Irvingia gabonensis seed
extract (active formulation) or oat bran (placebo). Three
capsules were taken three times daily, one-half hour
before meals (a total daily amount of 3.15 g of Irvingia
gabonensis seed extract) with a glass of warm water. Cap-
sules were identical in shape, colour and appearance, with
neither patients nor researchers knowing what capsule
they received. During the experimental period, subjects
were examined weekly, with their body weight, body fat,
waist and hip circumferences recorded each time. Subjec-
tive findings such as increased or decreased appetite, feel-
ing of lightness and gastrointestinal pains were
individually noted. Side effects of the active extract, if any
were also solicited and noted during each visit. The sub-
jects were also interviewed about their physical activity
and food intake during the trial, and were instructed to eat
a low fat diet (1800 Kcal) as well as keep a record for seven
consecutive days (using household measurements).
Table 1: Effect of Irvingia gabonensis crude extract on body weight, body fat, waist and hip circumferences
Treatment period (weeks)
024
Weight (kg Active 105.10 ± 16.98 102.3 ± 17.06 101.01 ± 16.63
Placebo 79.43 ± 9.83 79.43 ± 9.83 79.33 ± 10.63
Active 46.11 ± 4.4848 46.5 ± 3.68 45.34 ± 3.52
Body fat (%) Placebo 40.58 ± 3.49 40.58 ± 3.9 40.3 ± 3.8
Active 112.76 ± 20.5 109.7 ± 20.4 106.6 ± 20.79
Waist (cm) Placebo 81.1 ± 7.1 81,91 ± 7,91 81.25 ± 7.52
Active 125.69 ± 11.34 122.92 ± 10.67 121.15 ± 10.39
Hip (cm) Placebo 122.2 ± 10.7 122.2 ± 10.7 121.5 ± 10.9
Table 2: Effect Irvingia gabonensis on systolic (SBP) and diastolic (DBP) blood pressure
Treatment period (weeks)
024
SBP (mmHg) Active 136.41 ± 19.57 132.66 ± 18.48* 132.83 ± 17.97*
Placebo 134 ± 5.05 121.5 ± 5.89 123.83 ± 2.92
DBP (mmHg) Active 98.5 ± 19.52 97.5 ± 22.80 94.08 ± 11.07
placebo 93.50 ± 10.31 93.83 ± 7.41 91.5 ± 6.53
Values are means ± sem. Significant differences were at *P < 0.001 by comparison to the placebo group.
Table 3: The effect of Irvingia gabonensis on blood total cholesterol (TC), triglyceride (TRI), high density lipoprotein cholesterol 
(HDL-c), low density lipoprotein cholesterol (LDL-c) and glucose.
T-cholesterol TRI HDL-c LDL-c LDL/HDL T-cho/HDL GLUCOSE
Active Initial 215 ± 55.12 162 ± 33.15 61.23 ± 20.36 121.37 ± 36.3 1.98 ± 1.78 3.51 ± 2.70 3.8 ± 1.92
Final 130.68 ± 39.5 89.22 ± 55.63 89.9 ± 28.44 66.08 ± 34.27 0.735 ± 1.20 1.45 ± 1.38 2.57 ± 1.03
Placebo Initial 163.70 ± 
25.32
130.65 ± 
37.82
31.38 ± 25.21 105.06 ± 
11.86
5.05 ± 3.94 6.44 ± 3.37 3.6 ± 0.41
Final 158.36 ± 
30.46
100.52 ± 
32.55
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Anthropometric measurements
Anthropometric measurements were done at each visit,
with body weight and body fat (impedance measurement
using a TANITA™ monitor Scale) measurements on fasted
(12 hour) subjects wearing light clothing. Waist and hip
circumferences were measured by soft non-stretchable
plastic tape on the narrowest and the widest parts of the
trunk.
Laboratory methods
Blood samples were collected after a 12 h overnight fast
into heparinized tubes at the beginning of the study, after
two weeks and at the end (4 weeks) of treatment. The con-
centrations of total cholesterol, triacylglycerol, HDL-cho-
lesterol, and glucose, in plasma were measured using a
commercial diagnostic kit (Cholesterol infinity, triglycer-
ides Int, EZ HDL™ cholesterol, EZ LDL™ cholesterol, Glu-
cose Trinder, respectively) from SIGMA Diagnostics
Statistical Analysis
Results are expressed as mean ± SEM except for anthropo-
metric measurements. Paired Student's t-test was carried
out on the start and end values of placebo and Irvingia
gabonensis capsules and also on the differences between
the placebo and Irvingia gabonensis crude extract.
Results
Effect on body composition
Irvingia gabonensis induced a decrease in weight of 2.91 ±
1.48% (p < 0.0001) after two weeks and 5.6 ± 2.7% (p <
0,0001) after one month. Although the percentage of
body fat was not significantly reduced with both placebo
and IG, the waist circumference (5.07 ± 3.18%; p <
0.0001) and hip circumference (3.42 ± 2.12%; p <
0,0001) were significantly reduced by IG. A reduction of
1.32 ± 0.41% (p < 0.02) and 2.23 ± 1.05% (p < 0.05) was
observed with the placebo after two and four weeks
respectively of treatment.
Effect on blood pressure
From the second week of experimentation, the systolic
blood pressure was significantly reduced by the active
extract (Table 2).
Effect on blood lipids components
The plasma total cholesterol cencentration was reduced
by 39.21%, triglyerides by 44.9% (p < 0,05) and LDL by
45.58%. This was accompanied by a significant increase
in HDL-cholesterol of 46.852%. The CT/HDL ratio (p <
0.05) and the blood glucose level were also reduced
(32.36%; p < 0.05). No significant change was observed in
the placebo group.
Discussion
The soluble fibre of the seed of Irvingia gabonensis like
other forms of water-soluble dietary fibres, are "bulk-
forming" laxatives. Irvingia gabonensis seeds delay stomach
emptying, leading to a more gradual absorption of dietary
sugar. This effect can reduce the elevation of blood sugar
levels that is typical after a meal [4]. Controlled studies
have found that after-meal blood sugar levels are lower in
people with diabetes given glucomannan in their food [5]
and overall diabetic control is improved with soluble
fibre-enriched diets according to preliminary [6] and con-
trolled [7,8] trials. One double-blind study reported that
glucomannan (8–13 grams per day) stabilized blood
sugar levels in people with the insulin resistance syn-
drome [9]. Like other soluble fibers, Irvingia gabonensis
seed fibre can bind to bile acids in the gut and carry them
out of the body in the faeces, which requires the body to
convert more cholesterol into bile acids [10]. This can
result in the lowering of blood cholesterol as well as other
blood lipids. Controlled double-blind [11,12] studies
have shown that supplementation with several grams per
day of soluble fibre significantly reduced total blood cho-
lesterol, LDL cholesterol, and triglycerides and in some
cases raised HDL cholesterol, these being comparable
with effects noticed with Irvingia gabonensis.
Considering the wide use of Irvingia gabonensis in the
preparation of various dishes in Cameroon, its use should
be further encouraged for the purposes of control of die-
tary lipids as well as for weight reduction.
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